PRIMARY PERITONEAL CAVITY CANCER
Clinical trials for PRIMARY PERITONEAL CAVITY CANCER explained in plain language.
Never miss a new study
Get alerted when new PRIMARY PERITONEAL CAVITY CANCER trials appear
Sign up with your email to follow new studies for PRIMARY PERITONEAL CAVITY CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug XMT-1660 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called XMT-1660 in about 319 people with advanced solid tumors, including breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. Researchers will also see if the drug shrinks tumors.…
Matched conditions: PRIMARY PERITONEAL CAVITY CANCER
Phase: PHASE1, PHASE2 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo targets tough ovarian cancer
Disease control Recruiting nowThis study tests if two drugs, senaparib and temozolomide, can shrink tumors in people with a certain type of ovarian cancer that has an ARID1A gene change. About 18 adults with recurrent or persistent clear cell or endometrioid ovarian, fallopian tube, or primary peritoneal canc…
Matched conditions: PRIMARY PERITONEAL CAVITY CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC